Vimta Labs (524394) Q4 00/01 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 00/01 earnings summary
28 Oct, 2026Executive summary
FY2000-01 turnover reached a record ₹637.27 lakh, up 55% YoY; net profit after tax rose to ₹43.23 lakh from ₹7.37 lakh.
Testing and analysis services expanded amid domestic industrial recession; plans targeted foreign outsourcing demand and contract research.
Financial highlights
Revenue from operations was ₹637.27 lakh versus ₹410.92 lakh; profit before tax was ₹47.25 lakh versus ₹7.37 lakh.
Profit after tax was ₹43.23 lakh versus ₹7.37 lakh; amortization of preliminary and deferred revenue expenses was ₹13.10 lakh in both years.
Finance charges rose to ₹47.94 lakh from ₹31.09 lakh; depreciation increased to ₹55.09 lakh from ₹42.43 lakh.
Net cash from operating activities was ₹148.18 lakh, while investing activities used ₹86.56 lakh and financing activities used ₹9.92 lakh.
Outlook and guidance
Despite domestic industrial recession, rising quality awareness was expected to support continued performance; foreign markets targeted testing and contract research outsourcing.
Foreign-exchange earnings were expected to increase substantially; imported state-of-the-art equipment qualified for a 5% concessional customs duty rate.
Latest events from Vimta Labs
- Q2 income grew 9.9% as biologics began commercial delivery.524394
Q2 26/27 - Turnover fell and losses emerged, while GLP certification strengthened export prospects.524394
Q4 96/97 - Recession drove a Rs 219.81 lakh loss as new inspection services offered growth potential.524394
Q4 97/98 - Returned to profit and cleared IDBI term debt through a one-time settlement.524394
Q4 99/00 - Turnover surged 75%, with record exports and expansion plans supporting the outlook.524394
Q4 01/02 - Revenue rose 81%, exports surged, and a fivefold capacity expansion was planned.524394
Q4 03/04 - FY03 growth surged as exports expanded and lab capacity investment accelerated.524394
Q4 02/03 - Net profit rose 66% as exports surged and major lab expansion advanced.524394
Q4 04/05 - Capacity-constrained growth drove expansion, with FY06/07 revenue targeted at Rs.90–100 crore.524394
Q4 05/06